LAVA Therapeutics N.V. announced the appointment of Fred M. Powell as Chief Financial Officer, effective today. Mr. Powell brings over 20 years of global CFO experience in the biopharmaceutical industry, including investor relations, administration, operations and information technology. Most recently, Mr. Powell served as the executive vice president and chief financial officer of Antares Pharma, playing a leading strategic role in the successful $1.0 billion acquisition of Antares by Halozyme Therapeutics in May 2022.

He was also CFO at Celator Pharmaceuticals (acquired by Jazz Pharmaceuticals), OraPharma Inc. (acquired by Valeant Pharmaceuticals International) and BMP Sunstone Corporation (acquired by Sanofi-Aventis) and held various positions of increasing responsibility at KPMG LLP. Mr. Powell is the vice chairman of the Advisory Board for Penn State Scranton. He holds a B.S. in accounting from Pennsylvania State University.